Integrated Drug Development 

Our Integrated Drug Development work aims to increase the speed and reliability of delivering innovative dementia medicines and to increase patients’ access to medicines, treatments and health technologies across the world.
 

Finance Team

Global Team Lead: Raj Long
Team Members: Kiki Edwards; Dr. Kiyoshi Kurakawa; George Vradenburg; Johannes Levin; Megan Zoschg-Canniere

Aims of the group

  • To increase the speed and reliability of the delivery of new dementia medicines, through creating an efficient and effective global treatment development pathway.
  • To increase patients’ access to dementia medicines, treatments and health technologies across the world.

Current work priorities

  • Identifying and engaging with key bodies that provide funds for, commission and/or enable access to dementia medicines and health technologies across the world (e.g. NICE in the UK).
  • Working with these bodies to develop and implement a global plan for developing effective dementia treatments and innovations.

Our Integrated Drug Development team members

Our Integrated Drug Development work is led by WDC vice chair Raj Long, who works with an expert and experienced global team of WDC members and associate members.
  • Raj Long
    Raj Long
    WDC Vice-Chair
  • Kiki Edwards
    Kiki Edwards
    WDC Member
  •  Kiyoshi Kurokawa, MD, PhD
    Kiyoshi Kurokawa, MD, PhD
    WDC Member
  • George Vradenburg
    George Vradenburg
    WDC Member and Trustee
  • Johannes Levin
    World Young Leaders in Dementia
  • Megan Zoschg-Canniere
    Team Member